Clik here to view.
Humanigen Reports Positive Phase 3 Topline Results Demonstrating That...
BURLINGAME, Calif. Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with...
View ArticleClik here to view.
DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the first patient was dosed in DESTINY-Lung02, a global phase...
View ArticleClik here to view.
Personalis Announces Collaboration with MapKure to Use Personalis’ NeXT...
MENLO PARK, Calif. Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration with MapKure, LLC, a clinical-stage company focusing on genetically...
View ArticleClik here to view.
ARPA Computation Platform Q1 Update: Better Performance, Usability, and Next...
SINGAPORE ARPA, a blockchain-based privacy-preserving computation network, released its Quarter One Update on March 24th, 2021. Over the past years and during the first quarter of 2021, ARPA...
View ArticleClik here to view.
Noxopharm Files Septic Shock Treatment Patent for Veyonda®
SYDNEY Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug,...
View ArticleClik here to view.
ImmunoScape Raises $14M To Advance Deep Immunomics Platform for...
SINGAPORE & SAN DIEGO ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a...
View ArticleClik here to view.
Noxopharm为Veyonda®申请败血症休克治疗专利
悉尼 (美国商业资讯)–澳大利亚临床阶段药物开发公司Noxopharm Limited (ASX:NOX)宣布申请一项国际专利，旨在保护实验性抗癌药物Veyonda® (idronoxil)在阻止COVID-19和流感病毒等感染相关败血症休克发病方面的使用。...
View ArticleClik here to view.
RubrYc Therapeutics宣布与Zai Labs达成研究合作和许可选择协议
加州圣卡洛斯 (美国商业资讯)–开发表位选择性疗法的临床前生物疗法公司RubrYc Therapeutics, Inc.今天宣布，已与Zai Labs, Inc.签订研究合作和许可选择协议，利用RubrYc的中尺度工程分子(MEM)平台来确定对某个未披露的肿瘤靶点具有增强生物学功能的单克隆抗体。 根据协议条款，RubrYc和Zai Labs将携手合作，运用RubrYc的Discovery...
View ArticleClik here to view.
Prestige Biopharma and Pharmapark Announce License and Supply Agreement to...
SINGAPORE Prestige BioPharma and Pharmapark LLC today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of...
View ArticleClik here to view.
Clik here to view.
LintonPharm、筋層非浸潤性膀胱がんの治療薬としてカツマキソマブを評価する第1／2相試験の実施を中国の保健当局（NMPA）が承認したと発表
中国・広州市 （ビジネスワイヤ） — 中国を拠点とし、がん免疫療法のための二重特異性T細胞誘導抗体の開発に傾注する臨床段階のバイオ製薬企業LintonPharm Co.,...
View ArticleClik here to view.
Vicarious Surgical Inc. and D8 Holdings Corp. Announce Definitive Business...
CHARLESTOWN, Mass., & HONG KONG Vicarious Surgical Inc. (“Vicarious” or “Vicarious Surgical” or the “Company”), a next-generation robotics technology company seeking to improve both cost and...
View ArticleClik here to view.
ROSALIND, HELiXrUS and Geninus Partner to Bring Powerful New Single Cell...
SAN DIEGO & SEOUL, South Korea ROSALIND®, a software leader in extracting meaningful insights from diverse pools of life science data, today announced that it has partnered with two Seoul-based...
View ArticleClik here to view.
ノクソファームが敗血症性ショック治療の効用でビヨンダの特許を出願
シドニー （ビジネスワイヤ） — オーストラリアの臨床段階医薬品開発企業であるノクソファーム・リミテッド（ASX:NOX）は、COVID-19やインフルエンザウイルスなどの感染症に伴う敗血症性ショックの発症を予防するために使用できるよう、抗がん剤の治験薬であるビヨンダ（イドロノキシル）を保護する目的で、国際特許を出願したと発表しました。...
View ArticleClik here to view.
GC Pharma Lights Up to Celebrate ‘World Hemophilia Day’
YONGIN, South Korea GC Pharma (formerly known as Green Cross Corporation), a South Korean biopharmaceutical company, participates in a campaign to celebrate World Hemophilia Day. As part of GC...
View ArticleClik here to view.
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b...
BURLINGAME, Calif. Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with...
View ArticleClik here to view.
PTT Invests in Lotus Pharmaceutical’s Strategic Partnership in South East Asia
TAIPEI, Taiwan Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), an Alvogen company, has announced the issuance of new shares through private placement to be...
View ArticleClik here to view.
Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the U.S. Food and Drug Administration...
View ArticleClik here to view.
アビオメッド、ImpellaのPROTECT IVランダム化対照試験に最初の患者を組み入れたことを発表
米マサチューセッツ州ダンバース （ビジネスワイヤ） — アビオメッド（NASDAQ:ABMD）は本日、PROTECT IV試験に最初の患者を組み入れたと発表しました。PROTECT...
View ArticleClik here to view.
Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side...
CAMBRIDGE, Mass. & SHANGHAI Detailed results from the Phase III AENEAS trial showed that treatment with aumolertinib resulted in a clinically significant improvement in progression-free survival...
View Article